Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 17 (2001), Issue 2, Pages 49-57

Cancer Proteomics: The State of the Art

Paul C. Herrmann,1 Lance A. Liotta,1 and Emanuel F. Petricoin III2

1Clinical Proteomics Program, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
2Clinical Proteomics Program, Division of Therapeutic Proteins, CBER, Food and Drug Administration, Bethesda, MD 20892, USA

Received 20 September 2001; Accepted 20 September 2001

Copyright © 2001 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Now that the human genome has been determined, the field of proteomics is ramping up to tackle the vast protein networks that both control and are controlled by the information encoded by the genome. The study of proteomics should yield an unparalleled understanding of cancer as well as an invaluable new target for therapeutic intervention and markers for early detection. This rapidly expanding field attempts to track the protein interactions responsible for all cellular processes. By careful analysis of these systems, a detailed understanding of the molecular causes and consequences of cancer should emerge. A brief overview of some of the cutting edge technologies employed by this rapidly expanding field is given, along with specific examples of how these technologies are employed. Soon cellular protein networks will be understood at a level that will permit a totally new paradigm of diagnosis and will allow therapy tailored to individual patients and situations.